关于控股股东、持股5%以上股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股东股份质押基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301331 证券简称：恩威医药 公告编号：2025-055 恩威医药股份有限公司 ■ 上述股东及其一致行动人累计质押股份数量占其所持公司股份数量比例超过50%，现就相关情况说明如 下： 1、本次股份质押不用于满足上市公司生产经营需求； 2、恩威集团及其一致行动人未来半年内到期的累计质押股份数量为14,140,836股，占其所持公司股份的 19.89%，占公司总股本的13.74%，对应融资余额为16,000万元；未来一年内到期的累计质押股份数量为 54,420,836 股，占其所持公司股份的76.54%，占公司总股本的52.89%，对应融资余额为55,600万元。公 司及其一致行动人具备相应的资金偿还能力，还款资金来源为自有及自筹资金。 3、截至本公告披露日，上述股东及其一致行动人不存在非经营性资金占用、违规担保等侵害上市公司 利益的情形； 4、上述股东及其一致行动人股 ...

格隆汇11月26日丨恩威医药(301331.SZ)公布，全资子公司河南信心药业有限公司（简称：信心药业） 于近日取得了药品监管部门换发的《药品生产许可证》。人参养荣膏、益肺健脾颗粒两个品种已完成委 托、受托生产的许可证换发，尚需河南信心药业有限公司完成生产地址变更及关联变更的备案后方能投 入生产。 ...

Core Viewpoint - Tianmu Pharmaceutical has experienced a significant turnaround in its financial performance in 2024, primarily due to increased revenue from health products and medical training services, largely supported by local enterprises in Qingdao [2][3][4]. Financial Performance - Tianmu Pharmaceutical's revenue for the first half of 2024 was 0.6 billion, with a net profit of -0.19 billion [3]. - In the second half of 2024, the company's revenue surged to 1.58 billion, accounting for 72.59% of the total annual revenue, with a net profit of 0.34 billion [4]. - The fourth quarter alone contributed 0.93 billion in revenue, representing 42.62% of the annual total [4]. Business Segments - Health products became the largest business segment for Tianmu Pharmaceutical in 2024, generating 0.68 billion in revenue, a 322% increase year-on-year [5]. - Medical training services followed, with revenue of 0.43 billion, marking a 286% increase [5]. Customer Base and Relationships - Eight out of the top ten customers for Tianmu Pharmaceutical's health products in 2024 were Qingdao-based companies, with six being construction-related firms [5]. - The company has been questioned regarding the sustainability of its new customer relationships, particularly with local construction firms linked to its controlling shareholder [5][6]. Acquisitions and Projects - In 2024, Tianmu Pharmaceutical acquired a 51% stake in Qingdao Simulation Medicine, which significantly contributed to its revenue growth [6]. - Qingdao Simulation Medicine won a project from the Qingdao Health Commission worth 39.55 million, enhancing Tianmu's financial performance [6][9]. Future Outlook - The sustainability of the revenue growth from Qingdao Simulation Medicine is under scrutiny, with the company planning to enhance its capabilities and pursue additional contracts for 2025 [10].